FUSEN PHARM (01652) rose more than 7%, reaching HK$0.88 by the time of writing, with a trading volume of HK$1.264 million. The surge follows the company's announcement on November 14 that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology, received approval from China's National Medical Products Administration for the market launch of "Azilsartan Potassium Tablets" (brand name: Kuainuoping), indicated for the treatment of primary hypertension.

The main component of "Azilsartan Potassium Tablets," azilsartan potassium, is an angiotensin II receptor antagonist. After oral absorption, it rapidly converts into the active metabolite azilsartan, which lowers blood pressure by blocking the angiotensin II hormone.

Notably, within the overall renin-angiotensin system (RAS) market, over 80% of the share is occupied by "sartan"-class drugs, including monotherapies and combination therapies. In 2022, sales of these drugs exceeded RMB 10 billion, highlighting their significant role in the hypertension treatment landscape.